Related by context. All words. (Click for frequent words.) 75 unresectable 74 curative resection 73 stage IIIB 73 medically inoperable 72 neoadjuvant therapy 72 chemoradiotherapy 72 radical nephrectomy 72 stage IIIA 72 liver metastasis 72 urothelial carcinoma 71 Surgical resection 71 neoadjuvant chemotherapy 71 mucinous 71 resected 71 IV NSCLC 71 renal tumors 71 colorectal liver metastases 70 preoperative chemotherapy 70 hepatic metastases 70 metastatic renal cell carcinoma 70 pT2 70 cytoreduction 70 metastatic malignant 70 cytoreductive surgery 70 liver resection 70 carcinoids 70 underwent resection 70 prostate carcinoma 70 GISTs 69 recurrent glioblastoma multiforme 69 metastatic malignant melanoma 69 chemoradiation therapy 69 non squamous NSCLC 69 pneumonectomy 69 neoadjuvant 69 histologically confirmed 69 lymphadenectomy 69 localized renal 69 pancreatic adenocarcinoma 69 cystectomy 69 nonmetastatic 69 metastatic gastric 69 fallopian tube carcinoma 69 adjuvant radiotherapy 68 surgically resectable 68 completely resected 68 grade cervical intraepithelial 68 thymoma 68 transurethral resection 68 pelvic lymphadenectomy 68 esophagectomy 68 postoperative chemotherapy 68 mRCC 68 CTEPH 68 hepatocellular carcinomas 68 malignant pleural mesothelioma 68 locoregional 68 superficial bladder cancer 68 Hurthle cell 68 NMIBC 68 nodal metastasis 68 pT3 68 advanced adenomas 68 recurrent metastatic 68 EGFR mutation positive 68 metastatic bladder 68 total thyroidectomy 68 metastatic GIST 68 lymph node metastases 67 situ CIS 67 pulmonary metastases 67 liver metastases 67 concurrent chemoradiation 67 vinorelbine 67 chemoembolization 67 T1a 67 haematologic 67 Doxil ® 67 papillary renal cell carcinoma 67 metastatic RCC 67 adjuvant therapy 67 locoregional recurrence 67 peritoneal carcinomatosis 67 debulking surgery 67 lung resection 67 lymph node involvement 67 FOLFOX6 67 unresectable tumors 67 gastric adenocarcinoma 67 histologically 67 recurrent NSCLC 67 pancreatic carcinoma 67 LHRH receptor positive 67 metastatic HRPC 67 hematopoietic cancers 66 advanced adenoma 66 histologic subtype 66 conformal radiotherapy 66 EUS FNA 66 intravesical therapy 66 nephrectomy 66 Radical prostatectomy 66 differentiated thyroid 66 curative therapy 66 neoadjuvant treatment 66 fallopian tube cancers 66 neoplasias 66 pheochromocytoma 66 sentinel lymph node biopsy 66 advanced unresectable 66 node dissection 66 radical prostatectomy RP 66 gastroesophageal junction 66 sleeve lobectomy 66 benign nodules 66 peritoneal cancer 66 underwent surgical resection 66 Adjuvant chemotherapy 66 adenomatous 66 lymph node dissection 66 neoplasm 66 HGPIN 66 biochemical recurrence 66 intestinal metaplasia 66 adenomatous polyps 66 IIIA NSCLC 66 stage IIIb IV 66 histopathologic examination 66 chemoresistant 66 neoplastic lesions 66 malignant polyps 66 metastatic lesion 66 mitomycin C 66 metastatic colorectal 66 basal cell carcinoma BCC 66 pericardial effusion 66 needle aspiration 66 endobronchial 66 wedge resection 66 retroperitoneal 66 radioiodine therapy 66 adjuvant radiation 66 androgen deprivation 66 pituitary adenomas 66 taxane therapy 66 Gliadel Wafer 66 recurrent glioblastoma 66 metastatic liver 66 cervical carcinoma 66 dysplastic 66 colorectal cancer liver metastases 66 leiomyomas 66 biliary tract cancer 66 paraganglioma 66 surgical debulking 66 ALND 66 prostate cancer CaP 66 TACE 66 invasive carcinoma 66 tumors GIST 66 preoperative radiotherapy 65 histological subtype 65 tumor histology 65 radiochemotherapy 65 tumor resection 65 epithelial tumors 65 histologies 65 radical cystectomy 65 para aortic 65 CHOP chemotherapy 65 RALP 65 EGFR TKI 65 thyroid nodules 65 varices 65 gefitinib Iressa 65 HER2 negative 65 T1c 65 extracranial 65 Hepatocellular Carcinoma HCC 65 Papillary 65 hematologic toxicity 65 micrometastases 65 endoscopic ultrasonography 65 refractory NSCLC 65 chemotherapeutic regimens 65 esophageal gastric 65 metastatic lesions 65 castrate resistant 65 colorectal metastases 65 papillary 65 neoplasia 65 epithelial ovarian 65 conventional angiography 65 cytotoxic therapy 65 metastatic carcinoma 65 seminoma 65 thoracoscopic lobectomy 65 precursor lesions 65 adenoma 65 FDG-PET/CT 65 adjuvant chemotherapy 65 Radiofrequency ablation 65 pCR 65 radiotherapy RT 65 astrocytoma 65 ribavirin RBV 65 dasatinib Sprycel ® 65 6 mercaptopurine 65 surgical revascularization 65 Mitomycin C 65 paclitaxel carboplatin 65 premalignant 64 axillary dissection 64 heavily pretreated patients 64 resectable pancreatic cancer 64 biochemical relapse 64 advanced hepatocellular carcinoma 64 endometrial carcinoma 64 adenocarcinomas 64 ovarian carcinoma 64 TURP 64 thymectomy 64 pathologic diagnosis 64 gastrectomy 64 clinically localized prostate 64 TTF Therapy 64 lymph node metastasis 64 macroalbuminuria 64 distant metastases 64 HNSCC 64 axillary lymph node dissection 64 carcinoid tumors 64 micrometastasis 64 heavily pretreated 64 adriamycin 64 colorectal adenoma 64 sorafenib Nexavar 64 CYT# potent vascular disrupting 64 IIIb 64 patients undergoing CABG 64 docetaxel Taxotere ® 64 lobectomy 64 erlotinib Tarceva ® 64 perioperatively 64 malignant neoplasm 64 antiangiogenic therapy 64 EBRT 64 extracapsular extension 64 relapsed SCLC 64 malignant ovarian 64 Lenalidomide 64 gastric carcinoma 64 relapsed MM 64 cytoreductive nephrectomy 64 receptor tyrosine kinase inhibitor 64 cervical lymph nodes 64 histologically proven 64 mediastinal lymph nodes 64 intra arterial 64 stenoses 64 liposomal doxorubicin 64 VATS lobectomy 64 hormone refractory 64 cytologically confirmed 64 Neoadjuvant chemotherapy 64 contralateral breast 64 non resectable metastatic 64 malignant lymphoma 64 CIN3 64 endometrioid 64 operable breast cancer 64 unresectable stage 64 KRAS mutations occur 64 polypoid 64 prostate carcinomas 64 metachronous 64 5FU 64 partial nephrectomy 64 gastrointestinal stromal tumors GIST 64 transthoracic 64 metaplasia 64 gastrointestinal stromal tumor 64 MAGE A3 ASCI 64 malignant neoplasms 64 external beam radiotherapy 64 excisional biopsy 64 platinum refractory 64 squamous 64 urothelial cancer 63 HBeAg negative 63 thromboembolic events 63 carcinoid tumor 63 interferon alfa 2b 63 CR nPR 63 hyperplastic 63 FDG PET imaging 63 grade dysplasia 63 intraperitoneal chemotherapy 63 artery embolization 63 Immunohistochemical staining 63 anaplastic 63 endoscopic resection 63 follicular lymphoma FL 63 KRAS wild 63 hepatocellular carcinoma HCC 63 tumor lysis syndrome 63 BRCA deficient 63 receiving highly emetogenic 63 nodal metastases 63 transarterial 63 Flu Cy 63 myeloablative 63 hypofractionated 63 TKI therapy 63 cytotoxic chemotherapy 63 distant metastasis 63 RECIST Response Evaluation Criteria 63 perioperative morbidity 63 trabectedin 63 skeletal metastases 63 gadolinium enhanced 63 hypercalcemia 63 idarubicin 63 hamartomas 63 imatinib resistant 63 cervical intraepithelial neoplasia 63 invasive carcinomas 63 chemoradiation 63 urothelial bladder cancer 63 metastatic lung cancer 63 intraepithelial neoplasia 63 metastatic pancreatic 63 F FDG PET 63 epirubicin 63 allogeneic stem cell 63 stereotactic radiotherapy 63 HoLEP 63 colon resection 63 curable cancers 63 percutaneous drainage 63 mediastinoscopy 63 PSA nadir 63 axillary lymph nodes 63 unresectable locally advanced 63 PCa 63 surgical excision 63 CsA 63 bladder carcinoma 63 neoplasms 63 Accelerated Partial Breast Irradiation 63 castration resistant 63 intraductal 63 alkylating agent 63 Squamous 63 palliation 63 colorectal neoplasms 63 occlusive disease 63 non squamous 63 colorectal carcinoma 63 carboplatin paclitaxel 63 FDG uptake 63 ischemic lesions 63 HER2 positive metastatic breast 63 BCG refractory 63 ErbB2 positive 63 tumor necrosis 63 parathyroidectomy 63 carcinoma HCC 63 nonsmall cell lung cancer 63 multimodality therapy 63 follicular thyroid cancer 63 lung nodules 63 lung carcinomas 63 neuroendocrine carcinoma 63 sarcomatoid 63 mitomycin 63 breast carcinoma 63 hepatectomy 63 gastroduodenal 63 liposomal amphotericin B 63 caspofungin 63 doublet chemotherapy 63 paroxysmal AF 63 epithelial ovarian cancer 63 CCyR 63 renal pelvis 63 standard chemotherapy regimens 63 situ LCIS 63 evaluable 63 endosonography 63 cystic lesions 63 EGFR HER2 63 osteosarcomas 63 pleomorphic 63 orthotopic 63 non metastatic osteosarcoma 63 RAS mutations 63 leukemia AML 63 spinal metastases 63 adjuvant trastuzumab 63 ß blockers 63 node metastases 63 adrenalectomy 63 situ DCIS 63 Gleevec resistant 63 Soft Tissue Sarcoma 63 KRAS mutation 63 imatinib Gleevec ® 63 recurrent GBM 63 resections 63 invasive ductal 63 catheter angiography 63 nab paclitaxel 63 vinca alkaloids 63 segmentectomy 63 squamous histology 62 esophagogastric 62 cisplatin chemotherapy 62 NSTE ACS 62 thromboembolic complications 62 soft tissue sarcomas 62 neurofibromas 62 TNF blocker therapy 62 IV melanoma 62 postoperative morbidity 62 ductal carcinomas 62 malignant lesions 62 lenalidomide dexamethasone 62 sirolimus eluting stents 62 pegylated liposomal doxorubicin 62 prospective multicenter study 62 lung nodule 62 metastatic 62 SLNB 62 ductal 62 K ras mutations 62 metastatic CRC 62 lung metastases 62 osteoid osteoma 62 immunomodulatory therapy 62 chemotherapy cisplatin 62 Pemetrexed 62 acetabular fractures 62 resistant hormone refractory 62 upper endoscopy 62 serrated polyps 62 transabdominal 62 5-FU/LV 62 axillary lymph node 62 histologic 62 squamous cell histology 62 percutaneous biopsy 62 mediastinal 62 nephron sparing surgery 62 stenotic 62 oral anticoagulation 62 vulvar intraepithelial neoplasia 62 gastrointestinal stromal tumor GIST 62 androgen ablation 62 grade gliomas 62 refractory AML 62 lymphadenopathy 62 transitional cell carcinoma 62 taxane resistant 62 imatinib Gleevec 62 metastatic neuroendocrine tumors 62 extranodal 62 prognostic indicator 62 gemcitabine carboplatin 62 Trastuzumab 62 urography 62 voriconazole 62 papillary thyroid carcinoma 62 hyperplastic polyps 62 alkylating agents 62 cell carcinoma 62 percutaneous transluminal coronary angioplasty 62 hypervascular tumors 62 oncologic outcomes 62 castration resistant prostate cancer 62 surgically resected 62 cutaneous melanoma 62 squamous carcinoma 62 malignant lesion 62 medullary thyroid cancer 62 Glioblastoma Multiforme 62 systemic ALCL 62 revascularized 62 paclitaxel cisplatin 62 CIN2 + 62 breast carcinomas 62 carcinoma 62 primary peritoneal 62 immunocompetent 62 astrocytomas 62 intracavitary 62 Sezary syndrome 62 esophagogastric junction 62 stage IIIB IV 62 metastatic adenocarcinoma 62 irinotecan chemotherapy 62 tyrosine kinase inhibitors TKIs 62 hilar 62 cranial irradiation 62 anthracycline taxane 62 mycosis fungoides 62 Xanafide 62 NSCLC 62 lobular carcinoma 62 minimally symptomatic 62 ara C 62 endometrial hyperplasia 62 colorectal adenocarcinoma 62 chemo radiotherapy 62 HER2 positive cancers 62 Adenomas 62 FOLFOX4 62 variceal hemorrhage 62 sonographically guided 62 acute GvHD 62 corticosteroid therapy 62 malignant growths 62 imatinib therapy 62 INCB# [003] 62 gastrointestinal stromal tumors 62 CIN2 62 cisplatin resistant 62 proliferative diabetic retinopathy 62 Follicular Lymphoma 62 endoscopic retrograde 62 malignant ascites 62 hyperoxaluria 62 Metastatic 62 HER2 overexpression 62 Platinol ® cisplatin 62 neutropaenia 62 KRAS oncogene 62 gemcitabine Gemzar ® 62 β blockers 62 cell carcinomas 62 GP IIb IIIa inhibitors 62 recanalization 62 enucleation 62 ABVD 62 hypervascular 62 transplantation HCT 62 basal cell cancers 62 sentinel nodes 62 chlorambucil 62 R0 resection 62 squamous cell carcinoma SCC 62 hormone receptor positive 62 docetaxel chemotherapy 62 invasive coronary angiography 62 mCRC patients 62 subependymal giant cell 62 pulmonary metastasis 62 ultrasonographic 62 AGILECT R 62 lenalidomide Revlimid R 62 Stage IIIb 62 5 fluorouracil leucovorin 62 intravesical 62 prognostic variables 62 pegylated interferon alfa 2b 62 intravenous bisphosphonates 62 TMP SMX 62 resection 62 FDG PET 62 orchidectomy 62 PEGylated Fab fragment 62 partial remissions 62 squamous cell lung cancer 62 KRAS status 62 hepatic lesions 62 lymph node removal 62 EBUS 62 radiofrequency ablation RFA 62 prostate adenocarcinoma 62 interferon ribavirin 62 5-fluorouracil/leucovorin 62 metastatic basal cell 62 Neoadjuvant 62 estramustine 62 aplasia 62 epithelioid 62 lymphovascular invasion 62 seminal vesicle invasion 62 anthracycline containing 62 immunosuppressive regimen 62 biliary strictures 62 paragangliomas 62 ZACTIMA 62 bladder tumors 62 taxane refractory 62 carotid stenosis 62 metastatic lymph nodes 62 specific antigen PSA 62 FOLFIRI 61 CLL SLL 61 metastatic breast 61 Duodenal 61 bilateral orchiectomy 61 hormonal therapies 61 total abdominal hysterectomy 61 ertapenem 61 thyroglobulin 61 colectomy 61 pretest probability 61 xanthine oxidase inhibitor 61 anti angiogenic therapy 61 Tarceva TM 61 Mitoxantrone 61 renal cell carcinomas 61 follicular lymphomas 61 Paraplatin ® 61 XELOX 61 gemcitabine Gemzar 61 EGFR mutation 61 mildly symptomatic 61 leiomyosarcoma 61 taxane chemotherapy 61 refractory multiple myeloma 61 relapsed ovarian cancer 61 dysplastic lesions 61 Bezielle 61 Navelbine ® 61 drug eluting stent implantation 61 mutant KRAS 61 intra arterial chemotherapy 61 lung metastasis 61 remission induction 61 primary hyperparathyroidism 61 Cystectomy 61 fosbretabulin 61 metastatic renal 61 precancerous condition 61 antiangiogenic agent 61 undetectable HBV DNA 61 fibrinolytic therapy 61 BRAF V#E mutation 61 fluoropyrimidine 61 bevacizumab Avastin 61 TRUS biopsy 61 advanced neoplasia 61 temsirolimus 61 metastases 61 transvaginal sonography 61 pleurodesis 61 gemcitabine chemotherapy 61 occult metastases 61 Lymph node 61 lumbar disk herniation 61 calcineurin inhibitor 61 DLTs 61 follicular NHL 61 somatostatin analog 61 tigecycline 61 #Gy 61 intensity modulated radiotherapy IMRT 61 cutaneous T 61 saphenous vein graft 61 fine needle aspiration 61 HSCT 61 malabsorptive 61 nodular 61 combretastatin A4 phosphate CA4P 61 Metastatic breast cancer 61 dacarbazine DTIC 61 progesterone receptor negative 61 urothelial 61 postoperative complication 61 mycophenolate 61 axillary nodes 61 transesophageal echocardiography 61 eribulin mesylate 61 postoperative radiotherapy 61 OPAXIO 61 invasive lobular carcinoma 61 Sentinel node biopsy 61 non splenectomized 61 adjuvant tamoxifen 61 hepatorenal syndrome 61 unfavorable cytogenetics 61 myelodysplastic myeloproliferative diseases 61 Toxicities 61 advanced metastatic renal 61 angioplasty stenting 61 pulmonary artery banding 61 neoplasia CIN 61 alefacept 61 Anaplastic 61 SIR Spheres 61 bleomycin 61 neutropenic 61 tumor xenograft models 61 elevated serum creatinine 61 DMARD therapy 61 proximal colon 61 vandetanib 61 antithymocyte globulin 61 paclitaxel eluting stents 61 small lymphocytic lymphoma 61 complete remissions 61 pancreatic NET 61 fluorouracil 61 QuadraSphere 61 palliative radiotherapy 61 adjuvant therapies 61 spiral computed tomography 61 hepatocellular carcinoma 61 splenic 61 HCV genotype 61 invasive lobular 61 calcineurin inhibitors 61 anaplastic astrocytoma AA 61 Postoperative complications 61 bronchogenic carcinoma 61 treat benign prostatic 61 pain palliation 61 #F FDG PET 61 ovarian malignancy 61 trans retinoic acid ATRA 61 prostate TURP 61 cholangiocarcinoma 61 carcinoid 61 mutated K ras 61 LV dysfunction 61 hepatocellular cancer 61 FUSILEV enhances 61 monophasic 61 preoperative staging 61 anterior uveitis 61 intraventricular 61 metastatic castration resistant 61 ischemic cardiomyopathy 61 endoscopic ultrasound 61 metastatic renal cell 61 interstitial pneumonia 61 lymphoid malignancies 61 clinicopathological features 61 colon carcinoma 61 thalidomide Thalomid 61 HER2 positive 61 BEACOPP 61 coronary revascularization 61 prostate cancer PCa 61 Irinotecan 61 MDCT angiography 61 multivessel disease 61 Selective Internal 61 primitive neuroectodermal tumor 61 carcinomas 61 transurethral 61 mutated KRAS 61 EBUS FNA 61 prior chemotherapy regimens 61 thrombocytopenic 61 GORE VIABAHN Endoprosthesis 61 Peginterferon alfa 2b 61 thyroidectomy 61 colorectal polyp 61 pharmacokinetic interactions 61 allogeneic HSCT 61 steatohepatitis 61 androgen independent 61 bladder cancers 61 hormone receptor negative 61 Group RTOG 61 aortic regurgitation 61 HER2 expression 61 calculi 61 cancer mCRC 61 relapsed refractory 61 Response Evaluation Criteria 61 conventional DMARDs 61 abacavir lamivudine 61 pamidronate 61 glycoprotein IIb IIIa inhibitors 61 ACTEMRA TM 61 mycophenolate mofetil 61 invasive ductal carcinoma 61 Hycamtin ® 61 PSADT 61 myocardial revascularization 61 diagnostic modality 61 histopathologic 61 MabCampath 61 pancreatic lung 61 oral rivaroxaban 61 PAOD 61 locoregional disease 61 ASCUS 61 mcg albinterferon alfa 2b 61 polyposis 61 autologous SCT 61 tumor recurrence 61 ALA PDT 61 polyp recurrence 61 mCi 61 nonoperative treatment 61 relapsed refractory multiple myeloma 61 abdominal hysterectomy 61 androgen suppression 61 prostatic adenocarcinoma 61 laparoscopic cholecystectomy 61 cisplatin gemcitabine 61 sclerosing 61 duplex ultrasonography 61 non resectable 60 dacarbazine 60 FOLFOX chemotherapy 60 vWD 60 cell lymphoma CTCL 60 cetuximab Erbitux ® 60 microwave hyperthermia 60 Mitral valve repair 60 castrate resistant prostate cancer 60 gastric cancers 60 atypical Hemolytic Uremic Syndrome 60 adenomyosis 60 Basal cell 60 VFEND 60 MALT lymphoma 60 malignant cancerous 60 IV metastatic melanoma 60 hip resurfacing arthroplasty 60 perioperative mortality 60 K#N 60 estrogen receptor progesterone receptor 60 revascularization procedures 60 benign neoplasms 60 essential thrombocythemia ET 60 prostate cancer CRPC 60 TNF Tumor Necrosis Factor 60 Erlotinib 60 recombinant tissue plasminogen 60 pulmonary resection 60 pimecrolimus cream 60 metastatic hormone refractory 60 nilotinib Tasigna ® 60 vinca alkaloid 60 Capecitabine 60 injected subcutaneously 60 sentinel node biopsy 60 ductal cancer 60 evaluating tivozanib 60 grade squamous intraepithelial 60 PEG IFN 60 meningiomas 60 graft occlusion 60 Aflibercept 60 DFMO 60 somatostatin analogues 60 symptomatic paroxysmal AF 60 antiretroviral naïve 60 DOXIL 60 hemorrhagic cystitis 60 graft dysfunction 60 mesotheliomas 60 ductal breast cancer 60 cilengitide 60 nonoperative 60 untreated metastatic melanoma 60 dexamethasone Decadron 60 premalignant lesions 60 prophylactic cranial irradiation 60 adenoma recurrence 60 Paraplatin ® carboplatin 60 papillomas 60 osteosarcoma Ewing sarcoma 60 myelodysplastic syndrome MDS 60 Glioblastomas 60 cTnI 60 intravesical instillation 60 chemotherapy regimens 60 EGFR mutations 60 BRIM2 60 micafungin 60 sentinel lymph nodes 60 GnRH agonists 60 systemic anaplastic large 60 plus gemcitabine 60 CINTREDEKIN BESUDOTOX 60 antithrombotic therapy 60 DMARD 60 thyrotoxicosis 60 malignant fibrous histiocytoma 60 nonrandomized 60 flutamide 60 revascularization procedure 60 bone metastasis 60 axillary node dissection 60 cerebral vasospasm 60 osteopenic 60 TAXUS Express Stent 60 nonmelanoma skin cancers 60 surrogate endpoint 60 grade glioma 60 PNH patients 60 severe neutropenia 60 cutaneous squamous cell carcinoma 60 benign moles 60 lymphocytic 60 arteriography 60 intratumoral 60 pertuzumab 60 RECIST criteria 60 rFVIIa 60 ethambutol 60 noncalcified 60 achieve sustained virologic 60 transrectal ultrasound guided 60 malignant nodules 60 chronic HCV 60 keloid scarring 60 penetrating keratoplasty 60 endarterectomy 60 cirrhotic patients 60 neuroendocrine cancers 60 Combination therapy 60 evaluable subjects 60 myeloproliferative diseases 60 stratifying patients 60 lymphocytosis 60 lobular carcinomas 60 refractory acute myeloid 60 mTOR inhibitors 60 TroVax ® 60 acute leukemias 60 primary percutaneous coronary 60 standard chemotherapy regimen 60 VELCADE melphalan 60 recurrent malignant glioma 60 mg/m2 dose 60 histological subtypes 60 esophageal carcinoma 60 pre operatively 60 Platinol 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 hypermethylated 60 STRIDE PD 60 precancerous cervical lesions 60 ADPKD 60 obstructive lesions 60 RF ablation 60 bevacizumab Avastin ® 60 benign lesions 60 genotypic resistance 60 invasive bladder 60 #.#ng/ml 60 pancreatic neuroendocrine tumors 60 oral Hycamtin 60 orchiectomy 60 SCCHN 60 lung pancreatic 60 CMV disease 60 systolic dysfunction 60 metastatic androgen independent 60 tricuspid regurgitation 60 extrapleural pneumonectomy 60 CIMZIA ™ 60 subtrochanteric 60 ribavirin therapy 60 ANCA associated 60 Chemoradiation 60 gastric cardia 60 assessing T DM1 60 Surgical excision 60 undergone radical prostatectomy 60 recurrent ovarian 60 transarterial chemoembolization 60 cirrhotic 60 primary aldosteronism 60 aspartate aminotransferase AST 60 K ras mutation 60 q#h 60 methotrexate therapy 60 immunohistochemical staining 60 recurrent prostate cancer 60 thromboprophylaxis 60 VP# [004] 60 riociguat 60 Stage IIB 60 guaiac 60 immunohistochemical 60 Stage IIIA 60 ximelagatran 60 ductal lobular 60 cervical lymph node 60 dasatinib Sprycel 60 underwent radical cystectomy 60 FOLPI 60 HBeAg positive patients 60 ELOXATIN 60 pretransplant 60 radiolabeled TM# 60 anaplastic astrocytoma 60 teratoma